Claims for Patent: 7,772,267

Summary for Patent: 7,772,267

Title:	Bicyclic modulators of androgen receptor function
Abstract:	There are provided compounds according to formula I ##STR00001## wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia. Also provided are pharmaceutical compositions containing such compounds and processes for preparing some of the compounds of the invention. Other embodiments are also disclosed.
Inventor(s):	Sun; Chong-qing (East Windsor, NJ), Hamann; Lawrence (Cherry Hill, NJ), Augeri; David (Princeton, NJ), Bi; Yingzhi (Plainsboro, NJ), Robl; Jeffrey (Newtown, PA), Huang; Yan-Ting (Pennington, NJ), Wang; Tammy (Lawrenceville, NJ), Holubec; Alexandra (Yardley, PA), Simpkins; Ligaya (Titusville, NJ), Sutton; James C. (Princeton Junction, NJ), Li; James J. (Pennington, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	11/931,282
Patent Claims:	1. A compound according to formula I ##STR00319## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is selected from hydrogen (H), alkenyl or substituted alkenyl, CO.sub.2R.sub.4, CONR.sub.4R.sub.4' and CH.sub.2OR.sub.4; R.sub.2 and R.sub.2' are each independently selected from hydrogen (H), alkyl, substituted alkyl, OR.sub.3, SR.sub.3, halo, NHR.sub.4, NHCOR.sub.4, NHCO.sub.2R.sub.4, NHCONR.sub.4R.sub.4' and NHSO.sub.2R.sub.4; and at least one of R.sub.2 and R.sub.2' is H or alkyl, with the exception that R.sub.2 and R.sub.2' can both be OR.sub.3 when R.sub.3 is not H; R.sub.3 in each functional group is independently selected from hydrogen (H), alkyl or substituted alkyl, CHF.sub.2, CF.sub.3 and COR.sub.4; R.sub.4 and R.sub.4' in each functional group are each independently selected from hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl; R.sub.5 and R.sub.5' are each independently selected from hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and heteroaryl or substituted heteroaryl, wherein at least one of R.sub.5 and R.sub.5' is hydrogen, or R.sub.5 and R.sub.5' taken together can form a double bond with oxygen (O), sulfur (S), NR.sub.7 or CR.sub.7R.sub.7'; R.sub.6 and R.sub.6' are each independently at each occurrence selected from hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and heteroaryl or substituted heteroaryl, wherein at least one of R.sub.6 and R.sub.6' is hydrogen, or R.sub.6 and R.sub.6' at each occurrence may be taken together can form a double bond with oxygen (O), sulfur (S), or CR.sub.7R.sub.7'; R.sub.7 and R.sub.7' in each functional group are each independently selected from hydrogen (H), OR.sub.4, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl and heteroaryl or substituted heteroaryl; G is an aryl, heterocyclo or heteroaryl group, wherein said group is mono- or polycyclic, and which is optionally substituted with one or more substituents selected from hydrogen, halo, CN, CF.sub.3, OR.sub.4, CO.sub.2R.sub.4, NR.sub.4R.sub.4', CONR.sub.4R.sub.4', CH.sub.2OR.sub.4, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl and heteroaryl or substituted heteroaryl provided that if G is aryl, it is not naphthyl and it is not substituted with alkoxy or alkynyl and it is not a dichloro substituted aryl; W is selected from (CR.sub.6R.sub.6'), C(R.sub.6)OR.sub.3, or C(R.sub.6)(NR.sub.4R.sub.4'); and n is 1 or 2; with the provisos that: (a) at least one of the following is true: (i) there is at least one occurrence of R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, R.sub.6', R.sub.7 or R.sub.7' in which said R.sub.4, R.sub.4', R.sub.5, R.sub.5', R.sub.6, R.sub.6', R.sub.7 or R.sub.7' is heteroaryl or substituted heteroaryl; (ii) G is heterocyclyl which is optionally substituted or heteroaryl which is optionally substituted; (iii) G is substituted with heteroaryl or substituted heteroaryl; (b) when R.sub.5 and R.sub.5' are taken together to form a double bond with oxygen or sulfur, R.sub.6 and R.sub.6' are taken together to form a double bond with oxygen or sulfur, and W is CR.sub.6R.sub.6' in which R.sub.6 is aryl or substituted aryl and R.sub.6' is H, alkyl or substituted alkyl, then G is not 3,5-dichlorophenyl, 3-chloro-5-trifluoromethylphenyl, 3,5-di-trifluoromethylphenyl, 2,6-dichloropyridin-4-yl, 2,6-ditrifluoromethylpyridin-4-yl, 2-chloro-6-trifluoromethyl or pyridin-4-yl, or a phenyl group having a 4-fluoro, 4-chloro, 4-bromo, 4-iodo, 4-methyl or 4-trifluoromethyl substituent; and (c) when R.sub.5 and R.sub.5' are taken together to form a double bond with oxygen or sulfur, R.sub.6 and R.sub.6' are taken together to form a double bond with oxygen or sulfur, and G is optionally substituted phenyl or optionally substituted pyridin-4-yl, then R.sub.1 is not aralkyl or substituted aralkyl. 2. A compound or salt according to claim 1 wherein G is selected from: ##STR00320## wherein R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are each independently selected from hydrogen (H), NO.sub.2, CN, CF.sub.3, OR.sub.4, CO.sub.2R.sub.4, NR.sub.4R.sub.4', CONR.sub.4R.sub.4', CH.sub.2OR.sub.4, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl and heteroaryl or substituted heteroaryl; A to F are each independently selected from N or CR.sub.9; L, P and Q are each independently selected from CR.sub.12R.sub.12'; R.sub.12 and R.sub.12' in each functional group are each independently selected from a bond or R.sub.1; and m is an integer of 0 or 1. 3. A compound or salt according to claim 2 wherein R.sub.1 is H or alkyl; R.sub.2 or R.sub.2' is OH; R.sub.5 and R.sub.5' are each H, or R.sub.5 and R.sub.5' are taken together to form a double bond with oxygen or sulfur; and R.sub.6 and R.sub.6' are taken together to form a double bond with oxygen or sulfur. 4. The compound or salt according to claim 2 wherein R.sub.8 is --CN. 5. A compound or salt according to claim 1 wherein n is 2. 6. A compound according to claim 5 which is selected from the group consisting of: ##STR00321## ##STR00322## and, or a pharmaceutically acceptable salt thereof. 7. A compound or salt according to claim 1 wherein n is 1. 8. A compound or salt according to claim 7 wherein G is a heterocyclyl group which is optionally substituted or a heteroaryl group which is optionally substituted. 9. A compound according to claim 8 which is selected from the group consisting of: ##STR00323## ##STR00324## or a pharmaceutically acceptable salt thereof. 10. A pharmaceutical composition, comprising: (a) a compound or salt according to claim 1; and (b) at least one pharmaceutically acceptable diluent or carrier. 11. The pharmaceutical composition according to claim 10, further comprising at least one additional therapeutic agent selected from parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics. 12. The pharmaceutical composition according to claim 11, wherein the additional therapeutic agent is selected from the group consisting of growth hormone secretagogues and growth hormone.

Details for Patent 7,772,267

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-05-17